How are Wilms' Tumors treated?
In general, pediatric cancers are rare compared to adult cancers and compared to other, non-cancer pediatric diseases.Given this fact, all children w ith WT should be considered for entry into a clinical trial.Treatment should involve a multidisciplinary team of cancer specialists, including a pediatric surgeon or urologist, a pediatric radiation oncologist, and a pediatric oncologist, all of whom have some experience in treating WT patients.
Extensive research in the treatment of WT has been done by the Wilms' Tumor Study Group, (WTSG), which is now part of the Children's Oncology Group (COG).The findings of the four National Wilms' Tumor Studies (NWTS) conducted by the WTSG have helped establish current treatment guidelines.These guidelines typically incorporate a combination of surgery, chemotherapy and, in some patients, radiation therapy.
General Treatment Modalities
Surgery
The most important role of surgery is to entirely remove the tumor without rupturing it, and visually assessing the surrounding area for possible local disease spread.Total removal of the involved kidney, known as a radical nephrectomy, together with sampling, or "biopsy" of specific abdominal lymph nodes, is the surgical procedure of choice.Partial removal of the kidney is not currently recommended, although it may be an option for very small tumors that are incidentally found by an ultrasound performed for another reason.The contralateral kidney should be felt and visually inspected.
As in all cancer surgeries, any suspicious-looking area should be sampled.Special titanium surgical clips should be placed at the borders of where the surgeon removes the tumor (margins of resection).In most patients, surgical removal up front is possible, and should be pursued.
Chemotherapy
Patients with very large or extensive tumors that can not be feasibly and safely removed by surgery can be considered for preoperative chemotherapy.Prior to starting chemotherapy, a biopsy through the abdominal skin (percutaneously) should be performed to officially establish the diagnosis.Preoperative chemotherapy makes tumor removal easier and may reduce the frequency of surgical complications.
The chemotherapy drugs commonly used in WT patients are dactinomycin, vincristine, and doxorubicin.Less commonly used are etoposide and cyclophosphamide.Mesna is not itself a chemotherapy drug, but is a m edication used to protect the bladder wall from the harmful effects of the chemotherapy.
Newborns and all infants less than 12 months old need a 50% reduction in chemotherapy doses compared to doses given to older children.This is an effort to decrease the chemotherapy toxicity seen in children of this age group studied in the NWTS studies while not compromising the overall efficacy of the treatment.
Radiation Therapy
There is a very limited role of radiation therapy in the treatment of WT, and is restricted largely to treating symptoms caused by widespread, Stage IV disease, (ie: palliation of metastatic disease).The use of radiation as part of the definitive treatment of non-Stage IV patients is discussed below in the stage-specific subsections.
Special Notes
The chemotherapy drug dactinomycin should not be administered during radiation therapy, as this can worsen the side effects of the radiation, aka "radiation recall".
Children treated for WT are at increased risk for developing second cancers.This risk depends on the intensity of their therapy, including both chemotherapy (doxorubicin) and radiation therapy.Certain genetic factors also likely play a role, as these predisposed the child to get WT in the first place.
Stage-specific Treatment Guidelines
Stage I Wilms' Tumor
Favorable and Unfavorable Histologies: Nephrectomy with lymph node sampling and 18 weeks of chemotherapy with vincristine and single-dose (pulse-intensive) dactinomycin.
* It may be possible to treat a subset of stage I WT patients with just surgery, without chemotherapy.The COG is planning a large study to address this question.
Stage II Wilms' Tumor
Favorable Histology: Nephrectomy with lymph node sampling and 18 weeks of chemotherapy with vincristine and pulse-intensive dactinomycin .
Unfavorable Histology, focal: Nephrectomy with lymph node sampling, abdominal irradiation, and 24 weeks of chemotherapy with vincristine, doxorubicin, and pulse-intensive dactinomycin.
Unfavorable Histology, diffuse: Nephrectomy with lymph node sampling, abdominal irradiation, and 24 weeks of chemotherapy with vincristine, doxorubicin, etoposide, cyclophosphamide, and mesna.
Stage III Wilms' Tumor
Favorable Histology: Nephrectomy with lymph node sampling, abdominal irradiation, and 24 weeks of chemotherapy with vincristine, doxorubicin, and pulse-intensive dactinomycin.
Unfavorable Histology, focal: Nephrectomy with lymph node sampling, abdominal irradiation, and 24 weeks of chemotherapy with vincristine, doxorubicin, and pulse-intensive dactinomycin.
Unfavorable Histology, diffuse: Nephrectomy with lymph node sampling, abdominal irradiation, and 24 weeks of chemotherapy with vincristine, doxorubicin, etoposide, cyclophosphamide, and mesna.
Stage IV Wilms' Tumor
Favorable Histology : Nephrectomy with lymph node sampling, abdominal irradiation based on the local stage of the tumor, bilateral pulmonary irradiation for patients with chest x-ray evidence of pulmonary disease, and 24 weeks of chemotherapy with vincristine, doxorubicin, and pulse-intensive dactinomycin.
Unfavorable Histology, focal: Nephrectomy with lymph node sampling, abdominal irradiation based on the local stage of the tumor, bilateral pulmonary irradiation for patients with chest x-ray evidence of pulmonary metastases, and 24 weeks of chemotherapy with vincristine, doxorubicin, and pulse-intensive dactinomycin.
Unfavorable Histology, diffuse: Nephrectomy with lymph node sampling, abdominal irradiation, whole-lung irradiation for patients with chest x-ray evidence of pulmonary metastases, and 24 weeks of chemotherapy with vincristine, doxorubicin, etoposide, cyclophosphamide, and mesna.
Stage V Wilms' Tumor
In the past, the surgical approach to bilateral WT was removal of the kidney with the larger lesion.However, removing one kidney may lead patients with bilateral WT to kidney failure down the road.Besides, studies do not show any survival difference in children who undergo initial bilateral biopsy followed by chemotherapy and surgery later, as compared with patients who have the surgery upfront and chemotherapy later.Thus, the surgical goal should be to preserve as much of the kidneys as possible in order to minimize the risk of late kidney failure.
Bilateral biopsies and lymph node sampling should be performed first.
Next, 6 weeks of chemotherapy should be given, after which the patient is reassessed.If imaging studies show no further reduction in tumor size, a second-look surgery (partial nephrectomy) should be performed if negative margins can be obtained.Otherwise, another biopsy should be done to confirm the presence of actual remaining tumor.
The use of chemotherapy and/or radiation therapy after the second-look operation will depend on the patient's response to the initial chemotherapy.More aggressive therapy is needed for patients with little response to initial therapy, as documented by the second surgical procedure. |